Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Jennifer Diamond

Concepts (297)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Triple Negative Breast Neoplasms
16
2024
198
6.330
 Why?
Breast Neoplasms
25
2025
2212
4.370
 Why?
Antineoplastic Agents
23
2023
2152
2.450
 Why?
Immunoconjugates
7
2023
123
2.450
 Why?
Antineoplastic Combined Chemotherapy Protocols
20
2025
1742
2.400
 Why?
Pyrimidines
9
2021
472
2.280
 Why?
Receptor, ErbB-2
12
2025
346
2.050
 Why?
Protein Kinase Inhibitors
11
2025
907
1.800
 Why?
Piperazines
4
2020
345
1.610
 Why?
Paclitaxel
6
2022
237
1.530
 Why?
Camptothecin
9
2023
122
1.520
 Why?
Neoplasms
14
2022
2681
1.470
 Why?
Pyrazoles
6
2021
425
1.330
 Why?
Ovarian Neoplasms
5
2025
562
1.280
 Why?
Quinoxalines
2
2020
67
1.250
 Why?
Antibodies, Monoclonal, Humanized
10
2024
815
1.210
 Why?
Azepines
3
2020
97
1.190
 Why?
Histone Deacetylase Inhibitors
4
2024
209
1.150
 Why?
Cyclin-Dependent Kinase 4
2
2018
45
1.060
 Why?
Cyclin-Dependent Kinase 6
2
2018
40
1.050
 Why?
Neutropenia
4
2022
157
0.840
 Why?
Gene Expression Regulation, Neoplastic
5
2020
1388
0.750
 Why?
Xenograft Model Antitumor Assays
11
2021
870
0.720
 Why?
beta Catenin
2
2020
252
0.710
 Why?
Breast Neoplasms, Male
2
2018
29
0.710
 Why?
Female
52
2025
73763
0.670
 Why?
Chemotherapy, Adjuvant
4
2023
375
0.660
 Why?
Receptors, Estrogen
3
2021
409
0.660
 Why?
Maximum Tolerated Dose
9
2022
204
0.660
 Why?
Benzoxazoles
1
2020
19
0.660
 Why?
Cancer Care Facilities
1
2020
43
0.650
 Why?
Carcinoma, Lobular
2
2018
48
0.650
 Why?
eIF-2 Kinase
1
2019
31
0.620
 Why?
Lymphocytes, Tumor-Infiltrating
2
2020
205
0.610
 Why?
Tumor Microenvironment
4
2024
669
0.600
 Why?
Anthracyclines
3
2023
43
0.590
 Why?
Humans
65
2025
138651
0.580
 Why?
Taxoids
3
2023
101
0.570
 Why?
Aged
25
2025
24024
0.560
 Why?
Aurora Kinase A
4
2020
55
0.550
 Why?
Carcinoma, Ductal, Breast
1
2018
81
0.540
 Why?
Drug Resistance, Neoplasm
4
2020
801
0.540
 Why?
Wnt Signaling Pathway
1
2019
196
0.540
 Why?
Trastuzumab
4
2023
96
0.540
 Why?
Pyridines
3
2025
494
0.530
 Why?
Aromatase Inhibitors
3
2025
58
0.510
 Why?
Pyrazines
2
2018
87
0.510
 Why?
Colonic Neoplasms
1
2018
245
0.500
 Why?
Myocardial Infarction
1
2023
1059
0.490
 Why?
Tumor Suppressor Protein p53
4
2024
525
0.470
 Why?
Angiopoietin-1
1
2015
11
0.470
 Why?
Angiopoietin-2
1
2015
15
0.470
 Why?
Neoadjuvant Therapy
1
2018
412
0.460
 Why?
Neoplasm Recurrence, Local
5
2025
1057
0.460
 Why?
Nuclear Proteins
2
2023
706
0.460
 Why?
Medicare
4
2023
789
0.420
 Why?
Middle Aged
26
2025
33604
0.420
 Why?
Cell Line, Tumor
9
2022
3392
0.410
 Why?
Uterine Cervical Neoplasms
1
2017
282
0.410
 Why?
Colorectal Neoplasms
5
2022
777
0.400
 Why?
Adult
27
2025
38201
0.400
 Why?
Dose-Response Relationship, Drug
6
2022
2049
0.390
 Why?
Antibodies, Monoclonal
4
2024
1436
0.380
 Why?
Tumor Suppressor Proteins
1
2015
320
0.380
 Why?
Proto-Oncogene Proteins c-met
1
2013
72
0.380
 Why?
Treatment Outcome
13
2025
10923
0.380
 Why?
Cell Proliferation
8
2020
2480
0.380
 Why?
Recombinant Fusion Proteins
1
2015
663
0.380
 Why?
Antineoplastic Agents, Immunological
3
2019
190
0.380
 Why?
Point Mutation
1
2013
236
0.370
 Why?
Radiosurgery
3
2025
389
0.370
 Why?
Triazoles
1
2013
156
0.360
 Why?
Angiogenesis Inhibitors
3
2018
230
0.350
 Why?
Quinolines
3
2025
150
0.340
 Why?
Aged, 80 and over
10
2025
7677
0.340
 Why?
Mice, Nude
6
2020
688
0.340
 Why?
Carcinoma, Renal Cell
1
2013
212
0.330
 Why?
Clinical Trials, Phase I as Topic
2
2020
51
0.330
 Why?
Heart Failure
1
2023
2067
0.330
 Why?
Mitochondria
1
2017
955
0.330
 Why?
Histones
3
2023
632
0.320
 Why?
Genes, BRCA2
1
2009
30
0.320
 Why?
Neoplasm Metastasis
4
2020
666
0.320
 Why?
Genes, BRCA1
1
2009
41
0.310
 Why?
Biomarkers, Tumor
2
2014
1224
0.310
 Why?
Molecular Targeted Therapy
3
2019
413
0.300
 Why?
BRCA2 Protein
1
2009
62
0.300
 Why?
Pregnancy Complications, Neoplastic
1
2009
57
0.300
 Why?
Thrombophilia
1
2009
87
0.300
 Why?
Neoplasm Staging
5
2021
1372
0.290
 Why?
Kidney Neoplasms
1
2013
393
0.290
 Why?
Apoptosis
7
2024
2546
0.290
 Why?
Lung Neoplasms
2
2024
2527
0.290
 Why?
Receptors, Progesterone
2
2021
337
0.270
 Why?
DNA-Binding Proteins
1
2015
1471
0.270
 Why?
Models, Biological
1
2014
1806
0.250
 Why?
Mice
9
2021
17814
0.250
 Why?
Doxorubicin
3
2024
348
0.240
 Why?
Selective Estrogen Receptor Modulators
1
2025
32
0.230
 Why?
Cardiorespiratory Fitness
1
2025
57
0.230
 Why?
Cyclophosphamide
2
2018
255
0.210
 Why?
Disease Models, Animal
3
2021
4315
0.200
 Why?
United States
5
2023
14938
0.200
 Why?
Liver Neoplasms
1
2009
712
0.200
 Why?
Brain Neoplasms
3
2025
1267
0.190
 Why?
Biopsy
2
2018
1072
0.190
 Why?
Animals
11
2021
37217
0.190
 Why?
Cyclin-Dependent Kinase 9
1
2022
18
0.190
 Why?
Histone Deacetylase 1
1
2022
20
0.190
 Why?
Aurora Kinases
2
2012
28
0.180
 Why?
Administration, Oral
3
2022
788
0.180
 Why?
G2 Phase Cell Cycle Checkpoints
3
2022
44
0.180
 Why?
Topoisomerase I Inhibitors
2
2022
16
0.180
 Why?
Disease Progression
4
2019
2749
0.180
 Why?
Fluorouracil
1
2022
204
0.180
 Why?
Acetylation
1
2022
244
0.170
 Why?
Arrhythmias, Cardiac
1
2023
329
0.170
 Why?
Androstadienes
1
2021
78
0.170
 Why?
Biliary Tract Neoplasms
1
2021
29
0.170
 Why?
Diarrhea
2
2019
183
0.170
 Why?
Carboplatin
1
2021
146
0.170
 Why?
Heterografts
1
2021
135
0.170
 Why?
Drug Administration Schedule
3
2017
768
0.170
 Why?
Cancer Survivors
1
2025
289
0.170
 Why?
Hospitals, University
1
2021
175
0.170
 Why?
Necrosis
2
2019
248
0.170
 Why?
Histone Deacetylases
1
2022
209
0.160
 Why?
Fatigue
2
2022
336
0.160
 Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.160
 Why?
Immunotherapy
2
2023
634
0.160
 Why?
Clinical Trials as Topic
3
2016
1034
0.160
 Why?
Immune System
1
2021
181
0.160
 Why?
Benzodiazepines
1
2021
154
0.160
 Why?
Male
13
2021
68260
0.160
 Why?
Myeloid Cell Leukemia Sequence 1 Protein
1
2019
40
0.150
 Why?
Mechanistic Target of Rapamycin Complex 1
1
2020
129
0.150
 Why?
Kaplan-Meier Estimate
1
2021
896
0.150
 Why?
Tumor Cells, Cultured
1
2020
956
0.150
 Why?
Albumins
1
2019
115
0.140
 Why?
Aquaporin 4
1
2019
97
0.140
 Why?
Maintenance Chemotherapy
1
2018
37
0.140
 Why?
Vascular Endothelial Growth Factor A
2
2018
549
0.140
 Why?
Nausea
1
2018
111
0.140
 Why?
Aminopyridines
1
2018
102
0.140
 Why?
Antibodies, Bispecific
1
2018
55
0.140
 Why?
Mice, Inbred BALB C
1
2020
1262
0.140
 Why?
Drug Therapy, Combination
1
2020
1032
0.140
 Why?
Breast
1
2018
158
0.140
 Why?
Radiotherapy, Adjuvant
1
2018
215
0.130
 Why?
Purines
1
2018
179
0.130
 Why?
Benzimidazoles
1
2018
181
0.130
 Why?
Topotecan
1
2017
13
0.130
 Why?
Mastectomy
1
2018
148
0.130
 Why?
Isoflavones
1
2017
26
0.130
 Why?
Calcium-Binding Proteins
1
2018
215
0.130
 Why?
Imidazoles
1
2018
239
0.130
 Why?
Survival Analysis
1
2020
1309
0.130
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2017
18
0.130
 Why?
Carbolines
1
2017
32
0.130
 Why?
Programmed Cell Death 1 Receptor
1
2019
252
0.130
 Why?
Inhibitory Concentration 50
2
2016
89
0.130
 Why?
Retrospective Studies
4
2025
15909
0.120
 Why?
Neoplasms, Radiation-Induced
1
2016
91
0.120
 Why?
Hypertension
2
2018
1242
0.120
 Why?
Cell Survival
1
2019
1123
0.120
 Why?
Insulin-Like Growth Factor I
1
2018
325
0.120
 Why?
GPI-Linked Proteins
1
2016
76
0.120
 Why?
Neoplasms, Second Primary
1
2016
109
0.120
 Why?
Adaptor Proteins, Signal Transducing
1
2018
428
0.120
 Why?
Tumor Protein p73
1
2015
14
0.120
 Why?
Antibodies, Neoplasm
1
2015
33
0.120
 Why?
Nanoparticles
1
2021
469
0.110
 Why?
Carcinoma, Non-Small-Cell Lung
1
2024
1111
0.110
 Why?
Risk Reduction Behavior
1
2016
216
0.110
 Why?
Phosphorylation
1
2019
1760
0.110
 Why?
Hodgkin Disease
1
2016
154
0.110
 Why?
Maytansine
1
2014
17
0.110
 Why?
Demography
1
2015
296
0.110
 Why?
Brain Edema
1
2014
64
0.110
 Why?
Exercise
1
2025
2072
0.100
 Why?
Protein Kinases
1
2015
308
0.100
 Why?
Drug Interactions
1
2015
404
0.100
 Why?
Survival Rate
2
2019
1935
0.100
 Why?
Sulfones
1
2014
110
0.100
 Why?
Threonine
1
2013
47
0.100
 Why?
Randomized Controlled Trials as Topic
1
2019
1518
0.100
 Why?
Glycine
1
2014
174
0.100
 Why?
Tumor Stem Cell Assay
1
2012
34
0.100
 Why?
Drug Evaluation, Preclinical
1
2013
195
0.100
 Why?
Time Factors
2
2020
6851
0.100
 Why?
Drug Design
1
2013
165
0.100
 Why?
Methionine
1
2013
159
0.090
 Why?
Analgesics, Opioid
1
2021
1089
0.090
 Why?
Heterozygote
1
2013
305
0.090
 Why?
Disease-Free Survival
1
2014
704
0.090
 Why?
In Situ Hybridization, Fluorescence
1
2013
310
0.090
 Why?
Treatment Failure
1
2013
351
0.090
 Why?
Neovascularization, Pathologic
1
2013
296
0.090
 Why?
Cell Transformation, Neoplastic
1
2013
333
0.090
 Why?
Receptor Protein-Tyrosine Kinases
1
2013
231
0.090
 Why?
Carcinoma in Situ
1
2011
43
0.090
 Why?
Diabetes Mellitus, Type 2
1
2025
2490
0.090
 Why?
Cluster Analysis
1
2012
517
0.090
 Why?
Risk Assessment
1
2020
3433
0.090
 Why?
Computational Biology
1
2015
649
0.090
 Why?
Cellular Senescence
1
2012
191
0.080
 Why?
Risk Factors
2
2025
10252
0.080
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2010
85
0.080
 Why?
Colorado
1
2020
4555
0.080
 Why?
Mutation
2
2012
3987
0.080
 Why?
Sequence Analysis, DNA
1
2013
819
0.080
 Why?
Tumor Burden
1
2010
309
0.080
 Why?
Pregnancy Trimester, Second
1
2009
81
0.080
 Why?
Keratinocytes
1
2010
251
0.080
 Why?
Mastectomy, Segmental
1
2009
97
0.070
 Why?
Pregnancy Trimester, First
1
2009
137
0.070
 Why?
Apoptosis Regulatory Proteins
1
2009
192
0.070
 Why?
Lymph Node Excision
1
2009
168
0.070
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2009
116
0.070
 Why?
Risk
1
2009
893
0.070
 Why?
Infusions, Intravenous
2
2019
411
0.060
 Why?
Cell Adhesion Molecules
2
2019
178
0.060
 Why?
Prognosis
2
2018
3984
0.060
 Why?
Gene Expression Profiling
1
2012
1746
0.060
 Why?
Antigens, Neoplasm
2
2019
316
0.060
 Why?
Oxazoles
1
2025
36
0.060
 Why?
Cell Cycle Proteins
2
2023
616
0.060
 Why?
CD8-Positive T-Lymphocytes
2
2023
905
0.060
 Why?
Accelerometry
1
2025
109
0.050
 Why?
Cell Cycle
2
2018
592
0.050
 Why?
Combined Modality Therapy
2
2019
1235
0.050
 Why?
Quinazolines
1
2025
249
0.050
 Why?
Follow-Up Studies
2
2025
5112
0.050
 Why?
Mesylates
1
2022
6
0.050
 Why?
Ataxia Telangiectasia Mutated Proteins
1
2022
65
0.050
 Why?
Signal Transduction
2
2014
5086
0.050
 Why?
Oxygen Consumption
1
2025
710
0.050
 Why?
Clinical Protocols
1
2023
273
0.050
 Why?
Ligands
1
2024
665
0.050
 Why?
RNA, Small Interfering
1
2024
626
0.040
 Why?
Chimerism
1
2021
32
0.040
 Why?
Lymphocyte Subsets
1
2021
88
0.040
 Why?
Liver
1
2009
1805
0.040
 Why?
Lymphoid Tissue
1
2021
79
0.040
 Why?
Mice, SCID
1
2021
368
0.040
 Why?
Hormones
1
2020
140
0.040
 Why?
SEER Program
1
2021
220
0.040
 Why?
Mice, Inbred NOD
1
2021
593
0.040
 Why?
M Phase Cell Cycle Checkpoints
1
2018
24
0.040
 Why?
Tissue Distribution
1
2018
330
0.030
 Why?
Infant, Newborn
1
2009
6144
0.030
 Why?
Anemia
1
2019
175
0.030
 Why?
Insulin Resistance
1
2025
1222
0.030
 Why?
Pregnancy
1
2009
6829
0.030
 Why?
Cetuximab
1
2016
98
0.030
 Why?
Retreatment
1
2016
73
0.030
 Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2016
122
0.030
 Why?
Neoplasm Transplantation
1
2016
250
0.030
 Why?
Drug Screening Assays, Antitumor
1
2016
193
0.030
 Why?
Platinum
1
2016
51
0.030
 Why?
Blood Glucose
1
2025
2239
0.030
 Why?
History, Ancient
1
2015
52
0.030
 Why?
Proto-Oncogene Proteins p21(ras)
1
2016
262
0.030
 Why?
Hematopoietic Stem Cell Transplantation
1
2021
661
0.030
 Why?
Transcription Factors
1
2023
1697
0.030
 Why?
Databases, Genetic
1
2015
241
0.030
 Why?
Biomarkers
2
2016
4092
0.030
 Why?
DNA Damage
1
2017
422
0.030
 Why?
Cross-Sectional Studies
1
2025
5520
0.030
 Why?
Mice, Knockout
1
2021
3028
0.030
 Why?
Quality of Life
1
2025
2954
0.030
 Why?
Opioid-Related Disorders
1
2021
544
0.020
 Why?
Phenotype
1
2021
3139
0.020
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2015
253
0.020
 Why?
Drug Combinations
1
2013
346
0.020
 Why?
Intracellular Signaling Peptides and Proteins
1
2015
462
0.020
 Why?
Immunohistochemistry
1
2016
1731
0.020
 Why?
Biopsy, Needle
1
2011
187
0.020
 Why?
Proto-Oncogene Proteins
1
2014
620
0.020
 Why?
Cohort Studies
1
2021
5697
0.020
 Why?
HT29 Cells
1
2010
41
0.020
 Why?
Enzyme Inhibitors
1
2014
847
0.020
 Why?
Transcription, Genetic
1
2017
1470
0.020
 Why?
Protein-Tyrosine Kinases
1
2013
431
0.020
 Why?
ErbB Receptors
1
2013
609
0.020
 Why?
Ki-67 Antigen
1
2010
111
0.020
 Why?
Patient Selection
1
2013
676
0.020
 Why?
Capillary Permeability
1
2010
147
0.020
 Why?
Patient Satisfaction
1
2013
688
0.020
 Why?
Positron-Emission Tomography
1
2010
304
0.020
 Why?
Membrane Proteins
1
2015
1145
0.020
 Why?
Algorithms
1
2015
1740
0.020
 Why?
Magnetic Resonance Imaging
1
2019
3637
0.020
 Why?
Tomography, X-Ray Computed
1
2016
2698
0.010
 Why?
Adolescent
1
2024
21564
0.010
 Why?
Brain
1
2014
2792
0.010
 Why?
Young Adult
1
2014
13305
0.010
 Why?
Diamond's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (297) concept(s)
_
Co-Authors Expand Description
See all (73) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)